EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Outcomes with ibrutinib in patients with chronic lymphocytic leukaemia: Results from the German multicentre REALITY study

Anke Gerhardt, Steffen Dörfel, Holger Schulz, Rudolf Schlag, Lukas Vornholz, Sonja Nejad-Asgari, Manfred Welslau

European Journal of Haematology · 2024

DOI: 10.1111/ejh.14186 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Haematology, 2024. Verfasst von Anke Gerhardt und 6 weiteren Autor:innen. Beteiligte Einrichtung: Schwerpunktpraxis für Hämatologie und Onkologie Potsdam, Potsdam, Germany. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Adenine, Piperidines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Janssen-Cilag GmbH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To assess treatment adherence, effectiveness and safety outcomes of patients with chronic lymphocytic leukaemia (CLL) receiving ibrutinib in a real‐world setting.

Methods

Patients enrolled in REALITY were ≥18 years with a confirmed diagnosis of CLL and were receiving ibrutinib as a first‐line (1L), 2L or ≥3L therapy. Treatment retention, adherence, progression‐free survival (PFS), overall survival (OS) and time to next therapy were assessed at 1 and 2 years overall, by typology and by cytogenetic subgroups. PFS and OS were analysed using Kaplan–Meier methods.

Results

Exactly 302 patients were enrolled across 57 sites in Germany, from January 2017 to July 2021. One‐year retention rates were 69.9% overall (primary endpoint), 77.9% for 1L patients, and 77.6%/78.8% for high‐risk patients with del17p/ TP53 . At 2 years, PFS/OS rates were 77.8%/90.7% overall (1L, 82.7%/90.4%), and were consistent across cytogenetic subgroups. PFS rates were higher for 1L versus ≥3L patients. Patients with the low‐acceptance/low‐control typology at baseline were less likely to retain treatment at 1 year versus the high‐acceptance/high‐control typology. No new safety signals were observed.

Conclusions

The REALITY study provides further evidence of the effectiveness and safety of ibrutinib in patients with CLL in a real‐world setting, particularly in earlier treatment lines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellAdeninePiperidinesHumansMaleFemaleAgedMiddle AgedGermanyAged, 80 and overTreatment OutcomeProtein Kinase InhibitorsAdult

Stichwörter der Autor:innen

CLLadherencecytogenetic analysisibrutinibreal‐world evidenceretentiontypology

Substanzen

ibrutinibAdeninePiperidinesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Schwerpunktpraxis für Hämatologie und Onkologie Potsdam, Potsdam, Germany.
  • Onkozentrum Dresden, Dresden, Germany.
  • Praxis Internistischer Onkologie und Hämatologie, Frechen, Germany.
  • Hämatologisch-Onkologische Schwerpunktpraxis Würzburg, Würzburg, Germany.
  • Janssen-Cilag GmbH, Neuss, Germany.
  • MVZ am Klinikum Aschaffenburg, Aschaffenburg, Germany.

Förderung

  • Janssen-Cilag GmbH

Zitieren

APA

Gerhardt, A., Dörfel, S., Schulz, H., Schlag, R., Vornholz, L., Nejad-Asgari, S., & Welslau, M. (2024). Outcomes with ibrutinib in patients with chronic lymphocytic leukaemia: Results from the German multicentre REALITY study. European Journal of Haematology. https://doi.org/10.1111/ejh.14186

Vancouver

Gerhardt A, Dörfel S, Schulz H, Schlag R, Vornholz L, Nejad-Asgari S, et al. Outcomes with ibrutinib in patients with chronic lymphocytic leukaemia: Results from the German multicentre REALITY study. European Journal of Haematology. 2024. doi:10.1111/ejh.14186

BibTeX
@article{Gerhardt2024,
  author = {Gerhardt, Anke and Dörfel, Steffen and Schulz, Holger and Schlag, Rudolf and Vornholz, Lukas and Nejad-Asgari, Sonja and Welslau, Manfred},
  title = {Outcomes with ibrutinib in patients with chronic lymphocytic leukaemia: Results from the German multicentre REALITY study},
  journal = {European Journal of Haematology},
  year = {2024},
  doi = {10.1111/ejh.14186}
}
Kostenlos starten →